96. Crohn disease Clinical trials / Disease details
Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04966585 (ClinicalTrials.gov) | March 15, 2022 | 8/7/2021 | Pilot Study of Posaconazole in Crohn's Disease | A Multicenter Randomized, Double-Blinded, Placebo-Controlled Study of Posaconazole in Genetically-Defined Patients With Active Crohn's Disease | Crohn Disease;CARD9 S12N Risk Allele | Drug: Posaconazole Delayed Release Oral Tablet;Drug: Matching Placebo Tablet | Cedars-Sinai Medical Center | NULL | Not yet recruiting | 18 Years | 60 Years | All | 24 | Phase 4 | United States |